Spontaneous Bacterial Peritonitis

Clinical Comprehensive Guide: Spontaneous Bacterial Peritonitis (SBP)

1. Comprehensive Introduction & Overview

Spontaneous Bacterial Peritonitis (SBP) represents one of the most critical and life-threatening complications in patients suffering from decompensated cirrhosis with ascites. Defined as an infection of the ascitic fluid without an evident intra-abdominal surgically treatable source, SBP is a hallmark of advanced hepatic failure.

Unlike secondary peritonitis, which arises from perforated viscera or localized abscesses, SBP is characterized by the translocation of bacteria from the intestinal lumen into the peritoneal cavity, facilitated by systemic immune dysfunction and portal hypertension. Given its high mortality rate—historically exceeding 90% before the advent of modern antibiotic protocols—early recognition, rapid diagnostic paracentesis, and aggressive therapeutic intervention are the cornerstones of clinical management.

2. Deep-Dive: Etiology and Pathophysiology

The pathophysiology of SBP is a multifactorial process involving gut dysbiosis, bacterial translocation, and impaired systemic immunity.

The Mechanism of Translocation

1. Gut Permeability: Portal hypertension leads to congestive enteropathy, causing mucosal edema and disruption of tight junctions between enterocytes.
2. Bacterial Overgrowth: The small intestinal bacterial overgrowth (SIBO) commonly found in cirrhotic patients increases the pool of potentially pathogenic bacteria.
3. Immune Deficit: Cirrhotic patients exhibit "cirrhosis-associated immune dysfunction" (CAID). The liver, which normally filters bacteria via Kupffer cells, is bypassed by portosystemic shunts, allowing bacteria to reach the systemic circulation.
4. Ascitic Fluid Protein: Low levels of ascitic fluid protein (<1.5 g/dL) correlate with reduced opsonization capacity, making the fluid a fertile medium for bacterial proliferation.

Common Microbial Etiology

The majority of SBP cases are monomicrobial. The most frequent causative organisms are Gram-negative bacilli, though Gram-positive cocci are rising in incidence due to prophylactic antibiotic use.

3. Clinical Indications, Presentation, and Staging

Standard Clinical Presentation

SBP is notoriously insidious. Clinicians must maintain a high index of suspicion; the classic triad of fever, abdominal pain, and rebound tenderness is present in fewer than 30% of cases.

• Common Symptoms:
  • Acute decompensation of liver function (e.g., new-onset hepatic encephalopathy).
  • Unexplained fever or hypothermia.
  • Abdominal pain or discomfort.
  • Worsening ascites or renal impairment.
  • Ileus (paralytic).

Diagnostic Staging and Criteria

The diagnosis of SBP is established through the analysis of ascitic fluid obtained via diagnostic paracentesis.

Note: The PMN count is the "gold standard" for initiating empiric antibiotic therapy, even before culture results return.

4. Differential Diagnosis

It is imperative to distinguish SBP from secondary bacterial peritonitis (SBP vs. SBP-mimics).

1. Secondary Bacterial Peritonitis: Infection caused by a perforated hollow viscus (e.g., peptic ulcer, appendicitis).
2. Differentiation: Suspect this if the fluid shows Runyon’s criteria: Total protein > 1 g/dL, Glucose < 50 mg/dL, and LDH > upper limit of normal for serum.
3. Tuberculous Peritonitis: Often presents with chronic, high-protein ascites and elevated lymphocyte counts.
4. Pancreatitis: Can lead to sterile ascites with elevated amylase levels.
5. Malignant Ascites (Peritoneal Carcinomatosis): Usually associated with high-protein fluid and cytology showing malignant cells.

5. Diagnostic Testing Protocol

Every patient admitted with cirrhosis and ascites, or those demonstrating clinical deterioration, requires immediate investigation.

• Diagnostic Paracentesis: Must be performed at the time of admission or upon clinical suspicion.
• Bedside Inoculation: Ascitic fluid should be inoculated into blood culture bottles at the bedside to increase culture sensitivity.
• Laboratory Panel:
  • Complete Blood Count (CBC) with differential.
  • Comprehensive Metabolic Panel (CMP) to assess renal function (Creatinine/BUN) and liver synthetic function (INR/Albumin).
  • Ascitic fluid analysis: Cell count with differential, protein, albumin, and culture.

6. Treatment Strategy and Prognosis

Standard Antibiotic Regimen

• First-line therapy: Third-generation cephalosporins (e.g., Cefotaxime 2g IV every 8 hours) are the standard of care.
• Duration: Typically 5 to 7 days, depending on clinical response.
• Albumin Infusion: Administration of intravenous albumin (1.5 g/kg on day 1; 1 g/kg on day 3) is critical to prevent Hepatorenal Syndrome (HRS) and reduce mortality.

Risks and Complications

• Hepatorenal Syndrome (HRS): A major cause of death in SBP. Inflammatory cytokines cause renal vasoconstriction.
• Antibiotic Resistance: Increasing prevalence of multi-drug resistant (MDR) organisms requires careful local antibiogram review.
• Recurrence: The risk of recurrence within one year is approximately 70%. Long-term secondary prophylaxis with Norfloxacin or Trimethoprim-sulfamethoxazole is often required.

7. Frequently Asked Questions (FAQ)

1. Does every patient with cirrhosis and ascites need a paracentesis?

Yes, diagnostic paracentesis is mandatory for all patients admitted with cirrhosis and ascites, as well as those presenting with fever, abdominal pain, or unexplained renal function deterioration.

2. Can SBP occur without fever?

Absolutely. SBP often presents with subtle clinical signs. In elderly or debilitated patients, hepatic encephalopathy or worsening renal function may be the only presenting symptoms.

3. What is "Culture-Negative Neutrocytic Ascites" (CNNA)?

This is a condition where the PMN count is $\geq$ 250 cells/mm³ but the culture is negative. It is treated identically to SBP because the clinical prognosis and response to therapy are similar.

4. Why is albumin given with antibiotics?

Albumin expands plasma volume and acts as a scavenger for nitric oxide and inflammatory mediators, which protects the kidneys from the systemic vasodilation that occurs during infection.

5. When should I suspect secondary peritonitis?

Suspect secondary peritonitis if there is no clinical improvement within 48 hours of starting antibiotics, or if the fluid shows multiple organisms on Gram stain or high LDH/low glucose levels.

6. Can I use prophylactic antibiotics for all cirrhotic patients?

No. Prophylaxis is reserved for high-risk patients: those with previous SBP episodes, those with ascitic protein < 1.5 g/dL with impaired renal function, or those with active GI bleeding.

7. What is the mortality rate of untreated SBP?

Untreated SBP carries a mortality rate exceeding 90%. Even with treatment, in-hospital mortality remains around 20–30%.

8. Are there contraindications to paracentesis?

There are very few. Severe, uncorrectable coagulopathy or fibrinolysis is a relative contraindication, but usually, the risk of SBP outweighs the risk of bleeding.

9. Does the PMN count change after starting antibiotics?

Yes. A repeat paracentesis is generally not required unless the patient fails to improve clinically after 48-72 hours of appropriate antibiotic therapy.

10. How do I prevent recurrence?

Secondary prophylaxis is essential. Once an episode of SBP has resolved, patients should be placed on long-term daily antibiotics (e.g., Norfloxacin 400 mg daily) to prevent future translocation events.

8. Clinical Summary Table: Management Checklist

9. Conclusion

Spontaneous Bacterial Peritonitis remains a formidable challenge in hepatology. It represents a systemic failure of the body’s barrier defenses and immune surveillance. By adhering to strict diagnostic protocols—specifically the rapid assessment of ascitic PMN counts—and implementing early, aggressive intervention with third-generation cephalosporins and albumin, clinicians can significantly improve outcomes. Future management will likely focus on the role of the gut microbiome and targeted therapies for immune modulation to further reduce the incidence of this devastating complication.

Related Clinical Integration

In the management of Spontaneous Bacterial Peritonitis (SBP), timely clinical intervention is paramount to reducing patient morbidity and mortality. The diagnostic process begins with a Diagnostic paracentesis / بزل تشخيصي (خدمات رعاية عامة) to obtain ascitic fluid for cell count and culture, which remains the gold standard for confirming the diagnosis. Once SBP is suspected or confirmed, immediate empiric therapy with Broad-spectrum antibiotics / مضادات حيوية واسعة الطيف Standard is essential to cover common enteric pathogens. While specific inpatient protocols may vary, clinicians must be aware of long-term prophylactic strategies, which may involve agents such as Bactrim / باكتريم 160mg/800mg to prevent recurrence in high-risk patients, whereas medications like Augmentin / أوجمنتين 312.5 mg/5 mL are typically reserved for specific clinical scenarios or de-escalation therapy based on sensitivity results.